Cover Image
市場調查報告書

EpiCast Report:血管炎 - 至2024年的流行病學預測

EpiCast Report: Vasculitis - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 352145
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:血管炎 - 至2024年的流行病學預測 EpiCast Report: Vasculitis - Epidemiology Forecast to 2024
出版日期: 2016年01月01日 內容資訊: 英文 98 Pages
簡介

在 (美國、法國、德國、義大利、西班牙、英國、日本)全球主要7個國家血管炎和確診的發病數量 (15歲以上) ,從2014年的82,019件,預計到2024年達95,428件,以1.63%的年度成長率增加。

本報告提供全球主要7個國家的血管炎調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 血管炎的流行病學預測
    • 確診的發病數量
    • 確診的患者數
    • 確診的發病數量 (年齡標準化)等
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER110-15

Vasculitis is a group of heterogeneous disorders affecting persons of both sexes and all ages. These disorders are characterized by inflammation and necrosis of the blood vessels including the veins, arteries, and capillaries. There are various forms of vasculitis, and their clinical expressions may differ greatly in terms of symptoms observed, severity and duration of the disease depending on disease site and type of blood vessels involved.

Due to the lack of a uniformly accepted classification criteria for vasculitis, GlobalData epidemiologists obtained data for each vasculitis disorder from studies that categorized patients with vasculitis with the Chapel Hill Consensus Conference (CHCC) definitions, the 2012 revised CHCC definitions, the 1990 ACR definitions for select vasculitis disorders, the European Medicines Agency (EMA) algorithm, or by clinical diagnosis. Studies using the Hammersmith criteria, the Japanese Diagnostic Criteria, and the International Study Group Criteria were also included for eGPA, TA, and BD, respectively. This approach was taken by GlobalData epidemiologists in order to utilize data from the most pertinent and up-to-date studies on vasculitis in the forecast without missing potentially important studies.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of vasculitis (includes AAV, LVV, BD, and KD) for ages 15 and older will increase from 82,019 diagnosed incident cases in 2014 to 95,428 diagnosed incident cases in 2024, at an Annual Growth Rate (AGR) of 1.63% during the forecast period. GlobalData epidemiologists forecast that the diagnosed prevalent cases of selected vasculitis disorders (includes AAV, TA, and BD) for ages 15 years and older will increase from 137,603 diagnosed prevalent cases in 2014 to 145,229 diagnosed prevalent cases in 2024, at an AGR of 0.55% during the forecast period. GlobalData epidemiologists forecast that in 2024, the 5EU (France, Germany, Italy, Spain, and UK) will have the highest number of diagnosed incident and diagnosed prevalent cases, with 31,916 diagnosed incident cases and 58,073 diagnosed prevalent cases, accounting for 42% and 40% of the diagnosed incident and diagnosed prevalent cases in the 7MM, respectively.

Scope

  • The Vasculitis EpiCast Report provides an overview of the risk factors and global trends of selected vasculitis disorders in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The selected vasculitis disorders are anti-neutrophil cytoplasmic antibod-associated vasculitis (AAV) (microscopic polyangitis [MPA], granulomatosis with polyangitis [GPA], and eosinophilic granulomatosis with polyangitis [eGPA]), large vessel vasculitis (LVV) (giant cell arteritis [GCA] and Takayasu's arteritis [TA]), Beh?et's disease (BD), and Kawasaki disease (KD). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of AAV, LVV, BD, and KD, as well as the diagnosed prevalent cases of AAV, TA, and BD. Age and sex segmentations are also provided.
  • The vasculitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Vasculitis EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global vasculitis market.
  • Quantify patient populations in the global vasculitis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for vasculitis therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Vasculitis, 2014-2024
    • 3.5.1. Diagnosed Incident Cases of AAV
    • 3.5.2. Diagnosed Prevalent Cases of AAV
    • 3.5.3. Age-Standardized Incidence of AAV
    • 3.5.4. Diagnosed Incident Cases of LVV - TA and GCA
    • 3.5.5. Diagnosed Prevalent Cases of TA
    • 3.5.6. Age-Standardized Incidence of LVV
    • 3.5.7. Diagnosed Incident Cases of BD
    • 3.5.8. Diagnosed Prevalent Cases of BD
    • 3.5.9. Age-Standardized Incidence of BD
    • 3.5.10. Diagnosed Incident Cases of KD
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Vasculitis
  • Table 2: 2012 Revised CHCC Definitions of Vasculitides
  • Table 3: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of MPA
  • Table 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MPA
  • Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GPA
  • Table 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of GPA
  • Table 7: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of eGPA
  • Table 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of eGPA
  • Table 9: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GCA
  • Table 10: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of TA
  • Table 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of TA
  • Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of BD
  • Table 13: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of BD
  • Table 14: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of KD
  • Table 15: 7MM, Sources Not Used in Epidemiological Analysis of AAV, LVV, BD, and KD
  • Table 16: 7MM, Diagnosed Incident Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Table 17: 7MM, Diagnosed Prevalent Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Table 18: 7MM, Diagnosed Incident Cases of LVV, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Table 19: 7MM, Diagnosed Prevalent Cases of TA, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Table 20: 7MM, Diagnosed Incident Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Table 21: 7MM, Diagnosed Prevalent Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Table 22: 7MM, Diagnosed Incident Cases of KD, Ages ≤5 Years, Both Sexes, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Figure 2: 7MM, Diagnosed Prevalent Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Figure 3: 7MM, Age-Standardized Diagnosed Incidence of MPA, Ages ≥15 Years, Both Sexes, N, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of GPA, Ages ≥15 Years, Both Sexes, N, 2014
  • Figure 5: 7MM, Age-Standardized Incidence of eGPA, Ages ≥15 Years, Both Sexes, N, 2014
  • Figure 6: 7MM, Diagnosed Incident Cases of LVV, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Figure 7: 7MM, Diagnosed Prevalent Cases of TA, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Figure 8: 7MM, Age-Standardized Diagnosed Incidence of GCA, Ages ≥15 Years, Both Sexes, N, 2014
  • Figure 9: 7MM, Age-Standardized Diagnosed Incidence of TA, Ages ≥15 Years, Both Sexes, N, 2014
  • Figure 10: 7MM, Diagnosed Incident Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Figure 11: 7MM, Diagnosed Prevalent Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024
  • Figure 12: 7MM, Age-Standardized Incidence of BD, Ages ≥15 Years, Both Sexes, N, 2014
  • Figure 13: 7MM, Diagnosed Incident Cases of KD, Ages ≤5 Years, Both Sexes, N, 2014-2024
Back to Top